These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 18067024)

  • 21. Unusual fluid retention with imatinib therapy for chronic myeloid leukemia.
    Ostro D; Lipton J
    Leuk Lymphoma; 2007 Jan; 48(1):195-6. PubMed ID: 17325868
    [No Abstract]   [Full Text] [Related]  

  • 22. Imatinib trough levels in chronic myelogenous leukemia: does one dose fit all?
    Yeung DT; White DL
    Leuk Lymphoma; 2011 Feb; 52(2):165-7. PubMed ID: 21171867
    [No Abstract]   [Full Text] [Related]  

  • 23. Pregnancy on imatinib: fatal outcome with meningocele.
    Choudhary DR; Mishra P; Kumar R; Mahapatra M; Choudhry VP
    Ann Oncol; 2006 Jan; 17(1):178-9. PubMed ID: 16291579
    [No Abstract]   [Full Text] [Related]  

  • 24. Fatherhood during imatinib.
    Shash E; Bassi S; Cocorocchio E; Colpi GM; Cinieri S; Peccatori FA
    Acta Oncol; 2011 Jun; 50(5):734-5. PubMed ID: 21517714
    [No Abstract]   [Full Text] [Related]  

  • 25. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia.
    Agarwal A; Eide CA; Harlow A; Corbin AS; Mauro MJ; Druker BJ; Corless CL; Heinrich MC; Deininger MW
    Leukemia; 2008 Dec; 22(12):2269-72. PubMed ID: 18509354
    [No Abstract]   [Full Text] [Related]  

  • 27. Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.
    Murphy M; Close J; Lottenberg R; Rajasekhar A
    Am J Med Sci; 2014 Mar; 347(3):254-5. PubMed ID: 24553361
    [No Abstract]   [Full Text] [Related]  

  • 28. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
    Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
    Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055
    [No Abstract]   [Full Text] [Related]  

  • 29. Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy.
    Baldazzi C; Luatti S; Marzocchi G; Stacchini M; Gamberini C; Castagnetti F; Palandri F; Rosti G; Baccarani M; Testoni N
    Leuk Res; 2009 Dec; 33(12):e218-20. PubMed ID: 19525008
    [No Abstract]   [Full Text] [Related]  

  • 30. Imatinib in chronic myeloid leukemia elderly patients.
    Gugliotta G; Castagnetti F; Palandri F; Baccarani M; Rosti G
    Aging (Albany NY); 2011 Dec; 3(12):1125-6. PubMed ID: 22203437
    [No Abstract]   [Full Text] [Related]  

  • 31. Imatinib for chronic myeloid leukaemia: a NICE mess.
    Rajaratnam G; Edwards J
    Lancet; 2001 Dec; 358(9296):1902. PubMed ID: 11741655
    [No Abstract]   [Full Text] [Related]  

  • 32. Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate.
    Mesa RA; Steensma DP; Hoyer J; Ketterling RP
    Br J Haematol; 2003 Oct; 123(2):366-7. PubMed ID: 14531922
    [No Abstract]   [Full Text] [Related]  

  • 33. [Evolution of chronic myeloid leukemia on nilotinib after failure of imatinib].
    Sawadogo S; Hien FM; Ouédraogo MS; Drabo YJ
    Pan Afr Med J; 2014; 18():142. PubMed ID: 25419280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?
    White DL
    Leuk Lymphoma; 2008 Jun; 49(6):1022-3. PubMed ID: 18452091
    [No Abstract]   [Full Text] [Related]  

  • 35. New directions in the treatment of patients with chronic myeloid leukemia: introduction.
    Baccarani M
    Semin Hematol; 2009 Apr; 46(2 Suppl 3):S1-4. PubMed ID: 19621542
    [No Abstract]   [Full Text] [Related]  

  • 36. Application of comorbidity indexes at baseline could be useful to predict rates of response in patients with chronic myeloid leukemia treated with imatinib.
    Breccia M; Salaroli A; Serrao A; Zacheo I; Saracino R; Alimena G
    Leuk Lymphoma; 2014 Jan; 55(1):204-6. PubMed ID: 23586870
    [No Abstract]   [Full Text] [Related]  

  • 37. [Pregnancy and myeloid leukemia treated with imatinib. Development and monitoring of a patient].
    Báez-de la Fuente E; Arellano-Severiano B
    Rev Med Inst Mex Seguro Soc; 2014; 52(3):342-5. PubMed ID: 24878098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib.
    Chahardouli B; Zaker F; Mousavi SA; Saffari Z; Nadali F; Ostadali M; Ghadimi H; Alimoghaddam K; Ghavamzade A; Rostami S
    Hematology; 2013 Nov; 18(6):328-33. PubMed ID: 23676790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pregnancy outcome in chronic myeloid leukemia patients on imatinib therapy.
    Mukhopadhyay A; Dasgupta S; Kanti Ray U; Gharami F; Bose CK; Mukhopadhyay S
    Ir J Med Sci; 2015 Mar; 184(1):183-8. PubMed ID: 24590821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complete cytogenetic and molecular response to treatment with imatinib mesylate for philadelphia chromosome positive acute myeloid leukemia with multilineage dysplasia.
    Ueda K; Horiike S; Zen K; Misawa S; Taniwaki M
    Leuk Lymphoma; 2006 Sep; 47(9):1967-9. PubMed ID: 17065015
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.